JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
0.3
Cite Score
SJR: 0.114 / SNIP: 0.090
Volume 13, Issue 4 (2021)
Iran J War Public Health 2021, 13(4): 247-253 |
Back to browse issues page
Article Type:
Subject:
History
Received: 2021/09/4 | Accepted: 2021/10/4 | Published: 2022/01/24
Received: 2021/09/4 | Accepted: 2021/10/4 | Published: 2022/01/24
How to cite this article
Al-Sodani M, Wasfi Fadhil R, Al-Khayyad N, Dyab Allawi A. Acute Kidney Injury in Adult Iraqi Patients with COVID-19 Infection. Iran J War Public Health 2021; 13 (4) :247-253
URL: http://ijwph.ir/article-1-1027-en.html
URL: http://ijwph.ir/article-1-1027-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Department of Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq
2- Baghdad Teaching Hospital, Baghdad, Iraq
3- Kidney Transplant Center, Baghdad, Iraq
2- Baghdad Teaching Hospital, Baghdad, Iraq
3- Kidney Transplant Center, Baghdad, Iraq
Abstract (1934 Views)
Aims: Acute kidney injury patients with COVID-19 have worse outcomes than those without such complications. This study aimed to evaluate acute kidney injury in adult Iraqi patients with COVID-19.
Methods: This prospective study was performed on 250 patients with COVID-19. Laboratory parameters and chest computed tomography scan findings were gathered from the patient’s records. Patients were followed up for one week after hospital admission. According to Kidney Disease Improving Global Outcomes criteria, patients were categorized with and without acute kidney injury. The mortality rate, ICU admission, need for dialysis, and discharging well were recorded.
Findings: Incidence of acute kidney injury was 23.2% and had a significant correlation with older age (p=0.006) and hypertension (p=0.034). Chest and abdominal pain were more common in patients with acute kidney injury. The mean serum concentration of inflammatory markers (D-dimer and C-reactive protein) in acute kidney injury patients was 1863.60±1599.00ng/ml and 66.65±60.81ng/ml, compared with 1387.30±1099.00ng/ml and 42.95±34.35ng/ml, respectively in patients without acute kidney injury (p<0.05). 41.38% acute kidney injury patients and 59.38% without acute kidney injury were discharged well after one week, with a significant difference. The mortality rate was significantly higher in acute kidney injury patients, 12.07% versus 4.17% (p=0.026).
Conclusion: Old age, hypertension, chest and abdominal pain were more common in acute kidney injury patients with COVID-19. High D-dimer and CRP at presentation may be considered as good indicators for the possibility of acute kidney injury in patients with COVID-19. Acute kidney injury patients with COVID-19 have a low rate of discharging well & a higher mortality rate, and 10% need dialysis.
Methods: This prospective study was performed on 250 patients with COVID-19. Laboratory parameters and chest computed tomography scan findings were gathered from the patient’s records. Patients were followed up for one week after hospital admission. According to Kidney Disease Improving Global Outcomes criteria, patients were categorized with and without acute kidney injury. The mortality rate, ICU admission, need for dialysis, and discharging well were recorded.
Findings: Incidence of acute kidney injury was 23.2% and had a significant correlation with older age (p=0.006) and hypertension (p=0.034). Chest and abdominal pain were more common in patients with acute kidney injury. The mean serum concentration of inflammatory markers (D-dimer and C-reactive protein) in acute kidney injury patients was 1863.60±1599.00ng/ml and 66.65±60.81ng/ml, compared with 1387.30±1099.00ng/ml and 42.95±34.35ng/ml, respectively in patients without acute kidney injury (p<0.05). 41.38% acute kidney injury patients and 59.38% without acute kidney injury were discharged well after one week, with a significant difference. The mortality rate was significantly higher in acute kidney injury patients, 12.07% versus 4.17% (p=0.026).
Conclusion: Old age, hypertension, chest and abdominal pain were more common in acute kidney injury patients with COVID-19. High D-dimer and CRP at presentation may be considered as good indicators for the possibility of acute kidney injury in patients with COVID-19. Acute kidney injury patients with COVID-19 have a low rate of discharging well & a higher mortality rate, and 10% need dialysis.
References
1. Ronco C, Reis T, Husain‐Syed F. Management of acute kidney injury in patients with COVID‐19. Lancet Respir Med. 2020;8:738‐42. [Link] [DOI:10.1016/S2213-2600(20)30229-0]
2. Li Z, Wu M, Yao J, Guo J, Liao X, Song S, et al. Caution on kidney dysfunctions of COVID‐19 patients. medRxiv. 2020 Mar. [Link] [DOI:10.1101/2020.02.08.20021212]
3. Chaomin W, Xiaoyan Ch, Yanping C, Jia'an X, Xing Z, Sha X, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-43. [Link] [DOI:10.1001/jamainternmed.2020.0994] [PMID] [PMCID]
4. Wang L, Li X, Chen H, Yan S, Li D, Li Y, et al. Coronavirus disease 19 infection does not result in acute kidney injury: An analysis of 116 hospitalized patients from Wuhan, China. Am J Nephrol. 2020;51(5):343‐8. [Link] [DOI:10.1159/000507471] [PMID] [PMCID]
5. Rabi FA, Al Zoubi NS, Kasasbeh GhA, Salameh DM, Al-Nasser AD. SARS‐CoV‐2 and coronavirus disease 2019: What we know so far. Pathogens. 2020;9(3):231. [Link] [DOI:10.3390/pathogens9030231] [PMID] [PMCID]
6. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in hospital death of patients with COVID‐19. Kidney Int. 2020;97(5):829‐38. [Link] [DOI:10.1016/j.kint.2020.03.005] [PMID] [PMCID]
7. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID‐19 in the New York City area. JAMA. 2020;323(20):2052-9. [Link] [DOI:10.1001/jama.2020.6775] [PMID] [PMCID]
8. Bo Diao, Chenhui W, Rongshuai W, Feng Z, Zhang J, Yang H, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun. 2020;12:2506. [Link] [DOI:10.1038/s41467-021-22781-1] [PMID] [PMCID]
9. Soleimani M. Acute kidney injury in SARS‐CoV‐2 infection: Direct effect of virus on kidney proximal tubule cells. Int J Mol Sci. 2020;21(9):3275. [Link] [DOI:10.3390/ijms21093275] [PMID] [PMCID]
10. Diao B, Wen K, Chen J, Liu Y, Yuan Z, Han Ch, et al. Diagnosis of acute respiratory syndrome Coronavirus 2 infection by detection of nucleocapsid protein. medRxiv. 2020 Mar. [Link] [DOI:10.1101/2020.03.07.20032524]
11. Soler MJ, Wysocki J, Batlle D. ACE2 alterations in kidney disease. Nephrol Dial Transpl. 2013;28(11):2687‐97. [Link] [DOI:10.1093/ndt/gft320] [PMID] [PMCID]
12. Chu KH, Tsang WK, Tang CS, Lam MF, Lai FM, Fai To K, et al. Acute renal impairment in coronavirus‐associated severe acute respiratory syndrome. Kidney Int. 2005;67(2):698‐705. [Link] [DOI:10.1111/j.1523-1755.2005.67130.x] [PMID] [PMCID]
13. Ronco, Reis T, Husain-Syed F. Management of acute kidney injury in patients with COVID-19. Lancet Respir Med. 2020;8(7):738-42. [Link] [DOI:10.1016/S2213-2600(20)30229-0]
14. Wang K, Chen W, Zhou Y‐S, Lian JQ, Zhang Z, Du P, et al. SARS‐CoV‐2 invades host cells via a novel route: CD147‐spike protein. bioRxiv. 2020 Mar. [Link] [DOI:10.1101/2020.03.14.988345]
15. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. J Infect. 2020;80(6):607-13. [Link] [DOI:10.1016/j.jinf.2020.03.037] [PMID] [PMCID]
16. Huang C, Wang Y, Li X, Jiaping J, Hu Y, et al. Clinical features of patients infected with 2019 novel Coronavirus in Wuhan, China. Lancet Respir Med. 2020;395(10223):497-506. [Link] [DOI:10.1016/S0140-6736(20)30183-5]
17. Werns SW, Lucchesi BR. Myocardial ischemia and reperfusion: The role of oxygen radicals in tissue injury. Cardiovasc Drugs Ther. 1989;2:761-69. [Link] [DOI:10.1007/BF00133206] [PMID]
18. Jiang Hua, Deng Hongfei, Wang Yu. Lopinavir / ritonavir (LPV / r) for 2019 new crown the possibility of treatment of viral pneumonia: A rapid systematic review based on previous coronavirus pneumonia research. China J Emerg Med. 2020;29(2):182. [Link]
19. Alvarez-Belon L, Sarnowski A, Forni LG. COVID-19 infection and the kidney. Br J Hospital Med (Lond). 2020;81(10):1-8. [Link] [DOI:10.12968/hmed.2020.0574] [PMID]
20. Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):138. [Link]
21. Silva Borba MG, Almeida Val FF, Sampaio VS, Araújo Alexandre MA, Cardoso Melo G, Brito M, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: A randomized clinical trial. JAMA Netw Open. 2020;3(4):e208857. [Link] [DOI:10.1001/jamanetworkopen.2020.8857] [PMID]
22. Piano S, Dalbeni A, Vettore E, Benfaremo D, Mattioli M, Gambino CG, et al. Abnormal liver function testspredict transfer to intensive care unit and death in COVID-19. Liver Int. 2020;40(10):2394-406. [Link] [DOI:10.1111/liv.14565] [PMID] [PMCID]
23. Fominskiy EV, Scandroglio AM, Monti G, Calabrò MG, Landoni G, Dell'Acqua A, et al. Prevalence, characteristics, risk factors, and outcomes of invasively ventilated COVID-19 patients with acute kidney injury and renal replacement therapy. Blood Purif. 2021;50(1):102-9. [Link] [DOI:10.1159/000508657] [PMID] [PMCID]
24. Hong KS, Lee KH, Chung JH, Cheol Shin K, Young Choi E, Jung Jin H, et al. Clinical features and outcomes of 98 patients hospitalized with SARS-CoV-2 infection in Daegu, South Korea: A brief descriptive study. Yonsei Med J. 2020;61(5):431-7. [Link] [DOI:10.3349/ymj.2020.61.5.431] [PMID] [PMCID]
25. Lim J-H, Park S-H, Jeon Y, Cho JH, Jung HY, Choi JY, et al. Fatal outcomes of COVID-19 in patients with severe acute kidney injury. J Clin Med. 2020;9(6):1718. [Link] [DOI:10.3390/jcm9061718] [PMID] [PMCID]
26. Uribarri A, Nez-Gil InJ, Aparisi A, Becerra-Muñoz VM, Feltes G, Trabattoni D, et al. Impact of renal functionon admission in COVID-19 patients: An analysis of the international HOPE COVID-19 (Health outcome predictive evaluationfor COVID 19) registry. J Nephrol. 2020;29:1-9. [Link] [DOI:10.1007/s40620-020-00790-5] [PMID] [PMCID]
27. Trujillo H, Caravaca-Font F, Sevillano N, Gutiérrez E, Caro J, Gutiérrez E, et al. SARS-CoV-2 infection in hospitalized patients with kidney disease. Kidney Int Rep. 2020;5(6):905-9. [Link] [DOI:10.1016/j.ekir.2020.04.024] [PMID] [PMCID]
28. Imam Z, Odish F, Gill I, O'Connor D, Armstrong J, Vanood A, et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med. 2020;288(4):469-76. [Link] [DOI:10.1111/joim.13119] [PMID] [PMCID]
29. Fisher M, Neugarten J, Bellin E, Yunes M, Stahl L, Johns TJ, et al. AKI in hospitalized patientswith and without COVID-19: A comparison study. J Am Soc Nephrol. 2020;31(9):2145-57. [Link] [DOI:10.1681/ASN.2020040509] [PMID] [PMCID]
30. Arnold F, Westermann L, Rieg S, Neumann-Haefelin E, Biever PM, Walz G, et al. Superior anticoagulationstrategies for renal replacement therapy in critically ill patientswith COVID-19: A cohort study. BMC Nephrology. 2020 Jul. [Link] [DOI:10.1101/2020.06.26.20140699]
31. Husain-Syed F, Wilhelm J, Kassoumeh S, Birk HW, Herold S, Vadasz I, et al. Acute kidneyinjury and urinary biomarkers in hospitalized patients with Coronavirus disease 2019. Nephrol Dial Transplant. 2020;35(7):1271-4. [Link] [DOI:10.1093/ndt/gfaa162] [PMID] [PMCID]
32. Oussalah A, Gleye S, Urmes IC, Laugel E, Barbé F, Orlowski S, et al. Follow-up of multi-organdysfunction and inflammation using biomarker kinetics in patientswith severe COVID-19 disease and association with disease outcomes:Results from a referral center cohort in the north east of France. SSRN. 2020 Jun. [Link] [DOI:10.2139/ssrn.3590489]
33. Grimaldi D, Aissaoui N, Blonz G, Carbutti G, Courcelle R, Gaudry S, et al. Characteristics and outcomesof acute respiratory distress syndrome related to COVID-19 in Belgian and French intensive care units according to antiviralstrategies: The COVADIS multicenter observational study. Annals of Intensive Care. 2020;10:131. [Link] [DOI:10.1186/s13613-020-00751-y] [PMID] [PMCID]
34. Oksanen A, Kaakinen M, Latikka R, Savolainen L, Savela N, Koivula A. Regulation and trust: 3-month follow-up study on COVID-19 mortality in 25 European countries. JMIR Public Health Surveill. 2020;6(2):e19218. [Link] [DOI:10.2196/19218] [PMID] [PMCID]
35. Pei G, Zhang Z, Peng J, Liu L, Zhang Ch, Yu Ch, et al. Renal involvement and early prognosis in patients with COVID-19 pneumonia. J Am Soc Nephrol. 2020;31(6):1157-65. [Link] [DOI:10.1681/ASN.2020030276] [PMID] [PMCID]
36. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ. 2020;368:m1295. [Link] [DOI:10.1136/bmj.m1295] [PMID]
37. Zhou F, Wu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054-62. [Link] [DOI:10.1016/S0140-6736(20)30566-3]
38. Kolhe NV, Fluck RJ, Selby NM, Taal MW. Acute kidney injury associated with COVID-19: A retrospective cohort study. PLoS Med. 2020;17(10):e1003406. [Link] [DOI:10.1371/journal.pmed.1003406] [PMID] [PMCID]
39. Zhang J, Li J, Su L, Yung J, Jiang X, Jiang N, et al. Clinical characteristics and risk factors of acute kidney injury in coronavirus disease 2019. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020;32(4):407-11. [Chinese] [Link]
40. Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol. 2020;52(6):1193-4. [Link] [DOI:10.1007/s11255-020-02451-9] [PMID] [PMCID]
41. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. Eur Respir J. 2020;55(5):2000547. [Link] [DOI:10.1183/13993003.00547-2020] [PMID] [PMCID]
42. Angel-Korman A, Brosh T, Glick K, Leiba A. COVID-19, the kidney and hypertension. Harefuah. 2020;159(4):231-4. [Link]
43. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett R, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98(1):209-18. [Link] [DOI:10.1016/j.kint.2020.05.006] [PMID] [PMCID]
44. Zheng X, Yang H, Li X, Li H, Xu L, Yu Q, et al. Prevalence of kidney injury and associations with critical illness and death in patients with COVID-19. Clin J Am Soc Nephrol. 2020;15(11):1549-56. [Link] [DOI:10.2215/CJN.04780420] [PMID] [PMCID]
45. Robert-Ebadi H, Bertoletti L, Combescure C, Le Gal G, Bounameaux H, Righini M. Effects of impaired renal function on levels and performance of D-dimer in patients with suspected pulmonary embolism. Thromb Haemost. 2014;112:614-20. [Link] [DOI:10.1160/TH13-12-1024] [PMID]
46. Baer PC, Gauer S, Wegner B, Schubert R, Geiger H. C‐reactive protein induced activation of MAP‐K and RANTES in human renal distal tubular epithelial cells in vitro. Clin. Nephrol. 2006;66(3):177-83. [Link] [DOI:10.5414/CNP66177] [PMID]
47. Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao Sh, et al. AKI in Hospitalized Patients with COVID-19. J Am Soc Nephrol. 2021;32(1):151-60. [Link] [DOI:10.1681/ASN.2020050615] [PMID] [PMCID]
48. Hui D, Zumla A. Severe acute respiratory syndrome: Historical, epidemiologic, and clinical features. Infect Dis Clin North Am. 2019;33(4):869-89. [Link] [DOI:10.1016/j.idc.2019.07.001] [PMID] [PMCID]
49. Guan WJ, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of Coronavirus disease 2019 in China. New Engl J Med. 2020;382(18):1708-20. [Link] [DOI:10.1056/NEJMoa2002032] [PMID] [PMCID]